Your session is about to expire
← Back to Search
Study Summary
This trial is testing two different doses of a medication for kids with a rare disease called CIDP. The trial is open to kids who haven't tried this medication before, and also to kids who have tried it before but at a different dose.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 57 Patients • NCT01390649Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am between 2 and 17 years old with a diagnosis or suspicion of CIDP.I or my family have a history of inherited nerve damage.I do not have symptoms of CIDP.You have been diagnosed with developmental delay or regression.I am not using or willing to use birth control and am not abstaining from sex.You are allergic to Privigen.I have had a blood clot in the past.
- Group 1: IgPro10 (dose level 2)
- Group 2: IgPro10 (dose level 1)
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the government regulations concerning the use of IgPro10?
"Since this is a phase 4 trial, meaning that the treatment has already been approved, our team at Power estimates the safety of IgPro10 to be a 3."
Are there other examples of IgPro10 being studied in a clinical setting?
"IgPro10 was first studied in 2008 at Montefiore Medical Center. As of now, there have been 166 completed studies. 37 clinical trials are still recruiting patients, a number of them based in San Francisco."
Are investigators still recruiting participants for this research project?
"According to the latest update on clinicaltrials.gov, this clinical trial is looking for participants. The trial was originally posted on February 28th, 2019 and was most recently updated on August 24th, 2022."
Are there any inclusionary or exclusionary factors for potential participants of this research?
"Researchers are seeking 30 individuals, that are children or adolescents, to participate in this study. In order to qualify, potential participants must have a diagnosis of pediatric chronic inflammatory demyelinating polyneuropathy (cidp) and meet the following additional criteria: Male or female subjects 2 to ≤ 17 years of age with confirmed or possible CIDP."
For what purpose is IgPro10 most often prescribed?
"IgPro10 is an effective medical intervention for treating bruton's agammaglobulinemia, primary immunodeficiencies (pid), and agammaglobulinemia."
Are individuals aged 20 or more eligible to enroll in this clinical trial?
"According to the rules for who can participate in this trial, the minimum age is 2 and the maximum age is 17."
Is this clinical trial being conducted in more than one hospital in our state?
"There are 10 sites running this study at the moment, with locations in San Francisco, Norfolk, Iowa City and other places. If you choose to enroll in the study, try to select the site that is nearest to you to limit the amount of travel required."
Share this study with friends
Copy Link
Messenger